Ignite Creation Date:
2024-05-06 @ 1:41 AM
Last Modification Date:
2024-10-26 @ 11:08 AM
Study NCT ID:
NCT01870505
Status:
COMPLETED
Last Update Posted:
2022-03-02
First Post:
2013-06-03
Brief Title:
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Organization Data
Organization:
Memorial Sloan Kettering Cancer Center
Class:
OTHER
Study ID:
13-027
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Novartis Pharmaceuticals | INDUSTRY |